The National Comprehensive Cancer Network has published NCCN Guidelines for Patients: Small Bowel Adenocarcinoma.
The National Comprehensive Cancer Network took part in two events in Warsaw focused on advancing cancer care and highlighting the Poland-US bilateral achievements in health care May 21-22.
The American Association for Cancer Research has released its Cancer Disparities Progress Report 2024.
Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline in physical function, a UCLA-led study suggests.
Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.
Soligenix Inc. announced the results of its compatibility study evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma have been published in the Journal of the European Academy of Dermatology & Venereology Clinical Practice.
Alligator Bioscience has announced the initiation of a phase I clinical study (NCT06205849) to evaluate the safety and efficacy of mitazalimab (CD40 mAb agonist) injected intratumorally at the time of surgical irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer.
Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.
Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase III KeyVibe-010 trial.
ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.
